BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250703T190000
DTEND;TZID=Africa/Nairobi:20250703T203000
DTSTAMP:20260614T030708
CREATED:20250414T201819Z
LAST-MODIFIED:20250806T125526Z
UID:24411-1751569200-1751574600@kesho-kenya.org
SUMMARY:Lymphoma Management in Africa
DESCRIPTION:Date: 3 July 2025 | Time: 7:00 – 8:30 PM EAT \nModerator: Dr Beatrice Jepngetich \nDr. Anne Mwirigi – Relapsed/Refractory DLBCL \nDr. Anne Mwirigi presented a stage IVB germinal-center DLBCL case to illustrate why approximately 14% of Kenyan patients fail standard R-CHOP\, highlighting that true primary-refractory disease carries a median survival under nine months. She emphasized early risk stratification using IPI scoring\, interim PET imaging\, and molecular markers to identify high-risk individuals. For chemosensitive relapses\, salvage regimens such as R-GDP and R-ICE can bridge to autologous stem cell transplant; however\, CAR-T therapy and CD3×CD20 bispecific antibodies deliver the highest response rates. Practical recommendations included confirming residual disease with biopsy\, accelerating cellular therapy referral in primary-progressive cases\, and advocating for regional access programs to overcome cost barriers. \nDr. Jonathan Wawire – High-Grade B-Cell Lymphoma Entities \nDr. Jonathan Wawire decoded the WHO 5th-edition classification of high-grade B-cell lymphomas\, clarifying that a Ki-67 index ≥80% and dual MYC/BCL2 or BCL6 rearrangements define the most aggressive subtypes. He noted Kenya’s elevated prevalence of non-GCB and double-expresser lymphomas\, which correlate with poorer outcomes and necessitate intensified regimens. Key diagnostic insights included routine Ki-67 quantification\, Hans/Choi cell-of-origin algorithms\, and reflex FISH panels for precise double-hit detection. He stressed that accurate subclassification is essential for deciding when to intensify therapy beyond R-CHOP—such as DA-EPOCH-R—or to enrol patients in clinical trials\, ensuring truly personalized care for aggressive lymphoma in African settings.
URL:https://kesho-kenya.org/event/lymphoma-2/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/WhatsApp-Image-2025-06-29-at-8.28.07-AM-scaled-e1751238405443.jpeg
END:VEVENT
END:VCALENDAR